Astellas Pharma

Pharmaceuticals
4503.T
JPY 1,664 0.33
Share price
$ 20 bn
Market Cap
$ 24 bn
Enterprise Value

Carbon footprint

5.2 Ton
GHG emissions per $ 1 mln investment
0.15x the weighted average for S&P 500
FY2021
How is this calculated?
-26%
YOY change in GHG emissions
Stronger than the -11% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

but has a science based goal that does not target absolute reductions but is still aligned with Paris Agreement according to SBTi

GHG emissions and Carbon intensity

Astellas Pharma's GHG emissions (market-based) (Kt of CO2e)
Astellas Pharma's Carbon intensity (Tons per 1 USDm)

Astellas Pharma's carbon footprint

Astellas Pharma reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 March 2021 at 123 Kt (-44 /-26.2% y-o-y). Also positively, carbon intensity was down at 14 t (-1.6 /-10.1% y-o-y).

No public disclosure of Scope 3 emissions has been found for Astellas Pharma at the moment.

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Astellas Pharma also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. Astellas Pharma Inc. commits to reduce absolute scope 1 and 2 GHG emissions 63% by FY2030 from a FY2015 base year. Astellas Pharma Inc.commits to reduce absolute scope 3 GHG missions 37.5% by FY2030 from a FY2015 base year.

Company environmental metrics

Show more...